beta

AGLE

Aeglea Biotherapeutics, Inc.

Agle

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer. It develops pegzilarginase, its lead investigational therapy for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Market Cap: 229 Million

Primary Exchange: NASDAQ

Website: http://www.aegleabio.com

Shares Outstanding: 29 Million

Float: 24 Million

Dividend: (%)

Beta: 1.03641633930953

Sector: Health Technology

Industry: Pharmaceuticals: Major

Ethical Flags

Animal testing

Longest drawdown: 1447 trading days

From: 2016-04-08 To: 2019-12-06

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud